Pathological Tumor and Lymph Node Responses After Neoadjuvant Immunochemotherapy in Initially-unresectable NSCLC

Guangdong Provincial People's Hospital110 enrolled

Overview

This is a real-world study with the largest sample size investigating the pathological tumor and lymph node responses to neoadjuvant immunochemotherapy in non-small cell lung cancer to date. Patients with initially unresectable NSCLC underwent immunochemotherapy and response to treatment was assessed after every two treatment cycles. Clinicopathologic features of patients including epidemiological data, clinical manifestations, operation strategies, pathological findings, and prognostic information were recorded and evaluated.

Study Type

OBSERVATIONAL

Enrollment

110

Conditions

Non Small Cell Lung Cancer Immunotherapy Chemotherapy Tumour, Residual

Interventions

Timing of drug administration

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with stage III NSCLC who received neoadjuvant immunochemotherapy. * early-stage NSCLC patients who were initially unresectable. * 18 years of age or older. * Karnofsky performance status (KPS) score of 100 or 90. Exclusion Criteria: * Patients with stage IV NSCLC * Patients with known ALK translocations or EGFR mutations. * Karnofsky performance status (KPS) score \<90.

Outcomes

Primary Outcomes

Event-free survival

the time from diagnosis to any progression of disease precluding surgery, progression or recurrence of disease after surgery or death from any cause.

Time frame: At least one year